JAIDS Journal of Acquired Immune Deficiency Syndromes

BackgroundAlthough the number of new HIV diagnoses among men who have sex with men (MSM) in the Netherlands has declined considerably, the recent plateau suggests ongoing transmission. In 2024, 29% of new diagnoses among MSM were in a late HIV stage, showing that the time between infection and diagnosis can still be substantially reduced. In low-incidence settings, infections introduced through immigration are increasingly important in sustaining transmission, highlighting the need to re-evaluate current testing guidelines. We assess targeted testing strategies among MSM in the Netherlands addressing these considerations. MethodsWe used an agent-based model of HIV transmission among MSM in the Netherlands, incorporating infections acquired domestically and abroad. For 2024 - 2040, we simulated testing interventions targeting different subgroups, including offering an HIV test to immigrants upon entry, increasing testing rates among MSM residing in the Netherlands, and combinations of these approaches. ResultsOffering HIV testing to immigrating MSM at the entry averted up to 94 (95-th % quantile interval, 95% QI -128 - 328) new infections over 15 years if at least 50% take the test. Increasing testing to every 7 months in the general MSM population achieved the largest reduction, with up to 508 (95% QI 292 - 900) infections averted. The same testing rate in MSM with more than 5 partners within the previous six months resulted in 340 (95% QI 132-592) infections averted. Combining testing at entry with 7-months testing among general resident MSM averted the most infections, 534 (95% QI 308 - 884). ConclusionsCombination of offering HIV test to immigrating MSM at the entry with 7-month testing frequency in the general resident MSM population can substantially reduce HIV infections. The difference in impact between targeting general MSM and those with relatively high recent partner numbers suggests that criteria for being at risk of having HIV need to expand. 1 Author summaryWhile HIV transmission among MSM in the Netherlands has decreased substantially over the last decade, it is still ongoing. In 2024, 29% of new HIV diagnoses in MSM were in individuals in late-stage of HIV infection, suggesting that the time between HIV acquisition and diagnosis should be shortened further. Additionally, in a low-incidence setting such as MSM in the Netherlands, introduction of HIV infections through immigration becomes more important. We evaluated several HIV testing strategies for this context, considering both immigrating MSM and resident MSM. While offering HIV test at entry point can avert many HIV infections, increasing testing rate in resident MSM to on average every seven months can avert substantially more HIV infections. The greatest impact is achieved when these approaches are combined: targeting both immigrating MSM and those already living in the country. This combined strategy requires the fewest additional tests per infection averted. Importantly, our simulations show that there are MSM living with undiagnosed HIV who do not necessarily meet the traditional criteria for being at risk. Improved testing strategies can help reach these individuals earlier, benefiting both public and their personal health.

IntroductionUnderstanding provider preferences for the design of HIV treatment packages could enhance the implementation of programs to support the adoption of long-acting injectable antiretroviral therapy (LAI ART) by people living with HIV who are interested in initiating this treatment modality. MethodsWe recruited providers from New York City (NYC), Rockland, Putman, and Westchester County Ryan White Part A Medical Case Management (MCM) programs to complete a discrete choice experiment (DCE) containing twelve tasks with two alternatives and an opt-out option, with additional survey questions about implementation readiness and choice motivations. The alternatives included four attributes--Type of ART Medication (monthly or bimonthly LAI ART), Service Location and Mode, Support for Clients, and Rewards for Clients-- with 2-4 levels each. We ran latent class multinomial logit analyses (LCA) with 1-5 classes to estimate preferences and explore hypothesis-free preference heterogeneity. We estimated attribute influence using relative importances and preferences using zero-centered part-worth utilities for each level. ResultsOne hundred seventy-seven providers completed the survey (July 2022-January 2023). About half (52%) were 40-59 years old, 72% identified as women, and the plurality (41%) identified as Latino/a. We chose the two-group LCA solution. Bimonthly LAI ART was preferred over monthly LAI ART overall and in both groups. Group 1 (n=45) preferred more traditional adherence supports (e.g., injections at the clinic by appointment, injection appointment reminders) whereas Group 2 (n=132) preferred more client-centered supports (e.g., injections at home by appointment, free transportation to injection appointments if at a clinic). Both groups preferred higher monetary value gift cards for clients for every on-time injection. The top-ranking motivations indicated that participants prioritized patient convenience over job satisfaction and administrative or financial feasibility for the agency. The scores for all implementation measures indicate readiness to implement LAI ART in both groups. ConclusionsOur implementation science-focused study suggests that providers of MCM services in NYC and surrounding counties are motivated to offer services to support clients access and adherence to LAI ART. More work is needed to understand how programs have, in fact, integrated supports for LAI ART into their services.

Background African immigrants in the United States bear a disproportionate HIV burden, with incidence approximately sixfold higher than the general population, yet remain largely absent from targeted prevention research. HIV vulnerability among this population is mediated through relationship and family systems that are restructured by migration, reorganizing household composition, gender norms, trust, and communication patterns through which prevention engagement occurs. Despite this, migration has rarely been examined as a force that transforms the relational contexts shaping engagement with HIV testing, HIV self-testing (HIVST), and pre-exposure prophylaxis (PrEP). Methods The MiST-Pathways Study will use a sequential mixed-methods, community-based pilot design among first-generation African immigrant adults (ages 18-50) residing in New York and Massachusetts. The study will proceed in three phases: Aim 1 will use semi-structured interviews (n = 15) and a structured survey (n = 75) to identify relationship typologies and migration-related relational mechanisms influencing HIV prevention engagement; Aim 2 will employ Palava Hut Conversations (PHC) (an African-centered deliberative method) with up to 30 participants to co-develop and prioritize relationship-tailored intervention components; and Aim 3 will conduct a proof-of-concept assessment of the prioritized component using a single-group pre-post design (n = 24), incorporating surveys and cognitive interviews to assess feasibility, acceptability, and preliminary evidence of mechanism activation. All activities will be conducted virtually via Zoom and WhatsApp, with eligibility screening administered through REDCap. The study has been approved by the University at Buffalo Institutional Review Board (STUDY00010347) and registered at ClinicalTrials.gov (NCT07565584). Discussion This protocol outlines the planned evaluation of a sequentially designed, community-engaged pilot study to examine how migration reshapes relational contexts that influence HIV prevention decision-making among African immigrants. Findings will inform the development of culturally grounded, relationship-tailored prevention strategies and the design of a future, larger-scale intervention study.

BackgroundAdolescents and young adults with perinatally acquired HIV (APHIV) face complex psychosocial and structural challenges that may undermine resilience, a modifiable psychosocial determinant of treatment engagement, and health outcomes. Evidence on peer-led interventions targeting resilience among APHIV in South Asia remains limited. We evaluated resilience and its correlates among participants in the ImPossible Fellowship, a peer-led mentorship intervention in India. MethodsWe conducted a cross-sectional evaluation of 216 APHIV following completion of the 24-month ImPossible Fellowship in southern India in 2024. Surveys administered by trained youth investigators assessed sociodemographic, educational, and clinical characteristics. Resilience was measured using the Child and Youth Resilience Measure-Revised (CYRM-R), a validated multidimensional tool capturing personal and relational resilience dimensions. Low resilience was defined as CYRM-R threshold score [≤]33rd percentile. Multivariate logistic regression identified independent correlates of low resilience, and sensitivity analyses explored alternative CYRM-R thresholds. ResultsParticipants had a mean age of 18.7 years (range 9-24); 50% had no surviving parents, and 43% lived in child care institutions. Median resilience scores were high (74, Interquartile range [IQR] 69-78), and 91% achieved viral suppression. In multivariate analyses, three factors were independently associated with low resilience: loss of both parents (adjusted odds ratio [aOR] 4.35, 95% CI 2.09-9.06), school discontinuation (aOR 2.43, 95% CI 1.10-5.34), and self-reported communication barriers at HIV clinics (aOR 5.83, 95% CI 2.69-12.64). These associations were consistent across sensitivity analyses at alternative resilience thresholds. At the most stringent threshold of low resilience (CYRM-R score [≤]15th percentile), unsuppressed viral load also emerged as a significant correlate, suggesting that treatment failure may be concentrated among those with the most severely compromised resilience. ConclusionsAPHIV participating in a peer-led mentorship program demonstrated high overall resilience and viral suppression, but also revealed addressable vulnerabilities mapping to specific programmatic priorities. Peer-led models offer a promising foundational platform; however, complementary structural and psychosocial enhancements targeting these modifiable determinants are essential to optimize outcomes for those facing the greatest cumulative adversity.

IntroductionOn January 20, 2025, the U.S. government froze foreign assistance including for PEPFAR, though a limited waiver for "life-saving" interventions was subsequently granted. PEPFARs 2025 monitoring results, released April 17, 2026, covered only quarter 4 while an earlier inadvertent release included all four quarters. Combining both data sets, we systematically assess facility-level programmatic performance and reporting trends to quantify service disruptions accounting for reporting discrepancies. MethodsWe categorized facilities by reporting continuity across Q1 2024 and Q4 2025 (e.g. continuous, intermittent, dropped, or new) and assessed changes in service delivery by the category of health facility for key HIV treatment, testing, PMTCT, and prevention programming. We additionally analyze changes in employed human resources for health (HRH) reported by PEPFAR. ResultsPEPFAR data included 31,746 facilities and community service sites. 71.3% were classified as continuous reporters, 16.9% intermittent reporters, 2.5% community services, 3.9% dropped in 2025, and 3.1% new in 2025. Total number of people accessing HIV treatment declined modestly by -0.3%, but differed by facility category. Continuous facilities saw a 0.5% increase in people on treatment, while intermittent facilities saw a -1.7% decrease. HIV testing declined -17%. HIV diagnoses declined -13% in continuous facilities, -35% in community services, and -29% in intermittent facilities. PMTCT infant testing and diagnoses declined by -6% and -12% in continuous facilities, respectively, and -60% and -31% in intermittent facilities, respectively. PrEP initiations declined -33%. Total direct service delivery HCWs reduced -62,541 (-24%) ConclusionThese findings reveal substantial disruptions across PEPFAR service areas, with the steepest declines among intermittent and community-based delivery sites, alongside a 24% reduction in direct service delivery healthcare workers. As potentially the final data set PEPFAR will ever release, these findings represent a troubling inflection point. The dismantling of public data systems and accountability structures undermine progress and enable programmatic gaps to develop and go unnoticed that risk allowing HIV resurgence to occur over the coming years.

Transgender women are routinely recruited for HIV prevention research and describe feeling over-researched, undervalued, and disconnected from the benefits of research. Research fatigue refers to the adverse impacts of research participation from the volume, frequency, or intensity of research engagement. Research beneficence, an underdeveloped construct, refers to perceptions that research participation is empowering, appreciated, and beneficial to individuals and communities. This study sought to develop and psychometrically evaluate a research fatigue and beneficence scale and examine associations with cohort retention and study procedures among transgender women in the US and Puerto Rico. We developed a novel 7-item measure of research fatigue and beneficence informed by prior literature and qualitative work with transgender women. We assessed internal consistency reliability, factor structure, convergent and divergent validity, and predictive validity with 6-month study retention outcomes and procedures among 2189 transgender women enrolled in a US nationwide cohort (April 2023-December 2024) for the full 7-item research fatigue and beneficence scale, a 4-item research beneficence subscale, and a single-item research fatigue measure. Research beneficence items demonstrated good internal consistency (0.78) and excellent model fit. Research fatigue and beneficence varied by race/ethnicity with participants of color reporting both greater empowerment and greater concerns about community-level benefits. The item "I feel that I am asked to participate in research too frequently" was associated with lower 6-month retention, greater survey missingness, and preference for less invasive HIV testing modalities. Findings highlight multiple dimensions of research experience and the need for reduced participant burden, culturally tailored study designs, and intentional dissemination efforts to improve participant-centered research practices.

In the United States, gay, bisexual, and other men who have sex with men (MSM) experience a disproportionate burden of sexually transmitted infections (STIs), with notable racial/ethnic disparities. Doxycycline post-exposure prophylaxis (doxy-PEP) has emerged as a promising strategy to prevent bacterial STIs. This study analyzed 2023 National HIV Behavioral Surveillance data to examine doxy-PEP awareness, use, and intent to use among MSM in New York City (NYC), in a predominantly Hispanic/Latino sample. Among 134 participants, awareness and prior use were low (38.8% and 9.0%, respectively), but intent to use was high (75.4%). In Poisson regression models, intent was higher among participants reporting non-injection drug use and 2-10 partners in the past 12 months, while marginally lower among those above the Federal Poverty Level and recent migrants. Findings suggest doxy-PEP is acceptable for MSM in NYC, but addressing barriers among low-income groups and recent migrants is critical to reducing disparities.

Background: Pre-exposure prophylaxis (PrEP) has demonstrated a significant reduction in HIV infections among men who have sex with men (MSM), however, low medication adherence hinders its preventative effectiveness. Traditional approaches, such as health education and face-to-face inquiry (HEF), have demonstrated certain efficacy in improving PrEP adherence. However, these methods are resource-intensive and often plagued by delays, rendering timely and precise interventions challenging. This randomized controlled trial aims to assess the effectiveness of an intervention comprising AI-chatbot for PrEP (PrEP-bot) and Smart pillbox (SPB) (PrEP-bot-SPB) strategy to improve PrEP adherence among MSM compared to HEF.Methods and analysis: A three-arm, multicenter, open-lable RCT will be conducted with Chinese MSM [≥]18 years. A total of 300 participants will be recruited through three sources, including hospitals, community-based organizations (CBOs) and peer referral in five cities: Shenzhen, Beijing, Qingdao, Hangzhou and Zhengzhou. After completing baseline survey, participants will be randomized evenly into interventions or control groups: the PrEP-bot group, the PrEP-bot-SPB group, and the HEF control group. Participants in the PrEP-bot group will be granted access to an AI-chatbot agent through WeChat. This agent will: 1) generate personalized PrEP medication plans; 2) provide medication reminders and PrEP-related health check-ups notifications; 3) inquire about missed doses to deliver tailored interventions; 4) answer participant questions about PrEP using guideline-based knowledge. Participants in the PrEP-bot-SPB group will receive both the SPB and the PrEP-bot interventions. SPB could delivers medication reminders. Participants in HEF group will receive a health education pamphlet introducing PrEP and knowledge related to PrEP medication adherence at baseline and face-to-face inquiry every three months. Outcomes will be assessed for both short-term and medium-to-long-term effects. The primary objective is the effectiveness in improving PrEP adherence measured by self-report, Eight-Item Morisky medication adherence scale (MMAS-8) and concentration of Tenofovir in dried blood spots (DBS) (PrEP adherence [≥]90%) at 3 months follow-up. Secondary outcomes include: 1) effectiveness in preventing HIV infection measured by HIV-self test (HIVST); 2) effectiveness of PrEP-related health check-ups; 3) the effectiveness, feasibility, acceptability, and user satisfaction with the PrEP-bot; 4) effectiveness in improving PrEP adherence at 6-month, 9-month and 12-month follow-up periods. All participants will receive quarterly follow-up visits during the 12-month study period. Intention-to-treat analysis and per protocol set (PPS) analysis will be used.Results: Recruitment and enrollment of participants began in January 2026 and is currently ongoing.Discussion: This study is expected to establish a novel AI-based intervention model for PrEP, providing innovative strategies for HIV control among MSM populations. If the PrEP-bot is proven non-inferior to HEF, it could offer users real-time, precise, and personalized interventions while simultaneously addressing PrEP-related inquiries and health check-ups reminders. Importantly, this approach would achieve significant reductions in resource requirements for implementation and maintenance and be more cost-effective. With the ongoing advancement of AI technologies, PrEP-bot holds substantial promise for widespread implementation in PrEP adherence, potentially revolutionizing HIV prevention for MSM in China through this innovative intervention modality.Trial registration: ChiCTR2500111280 (Chinese Clinical Trial Registry). Date of registration: 29 October 2025.

Background Interruptions in HIV care pose a major challenge to achieving HIV control goals in many countries, with 30% of clients who initiate antiretroviral therapy (ART) in South Africa experiencing an interruption of >28 days during their first six months on treatment. South Africa introduced revised guidelines in 2023 to improve outcomes during this early treatment period, but guideline compliance remains incomplete and gaps in the support provided to both clients and providers to optimize service delivery and health outcomes. Protocol BRIDGE (Behavioral Risk Identification and Decision Guidance for Engagement) is a mixed-methods evaluation of a package of light-touch, low-cost interventions aimed at improving the experiences of both clients and providers of care, increasing compliance with the 2023 guidelines, supporting clients to remain in care, and ultimately reducing the incidence of missed visits during the early treatment period. Components of the BRIDGE Retention Toolkit include an intervention navigator to help clients self-assess areas of vulnerability for disengagement from care and identify appropriate interventions; client roadmap to explain the treatment journey for the early treatment period; WhatsApp-based counseling tool for clients; guideline reference for providers; and tracing job aids. The tookit will be piloted at 6-8 public sector primary health facilities for a one-month period. The primary outcome will be the probability of returning less than 28 days late for the next scheduled clinic visit, assessed using electronic medical record data for the pilot and comparison sites. Pilot outcomes will be compared to both their own probabilities prior to the pilot and to probabilities from comparable non-pilot facilities. Implementation outcomes to be assessed using qualitative interview data from both clients and providers will include reach, implementation fidelity, adoption (uptake), costs, feasibility, appropriateness, and acceptability. Discussion The evaluation will assess the implementation and preliminary effectiveness of a set of interventions designed to improve client outcomes during the early HIV treatment period. If some or all of the BRIDGE tools are found to be helpful and/or are associated with a reduction in missed clinic visits, they will comprise a readily scalable and affordable intervention to help address a major barrier in large-scale HIV treatment programs.

BackgroundHIV-related stigma remains a primary barrier to the elimination of the HIV epidemic worldwide. No studies have examined long-term changes in the distribution of stigmatizing attitudes within populations. MethodsWe conducted a whole-population, open cohort study of adults in 8 villages in rural southwestern Uganda, with 5 biennial surveys spanning 2014-2024 (N=1,776 at baseline; 869 participated in all waves). We measured individual negative attitudes toward people with HIV ("public stigma") and perceptions of negative attitudes among others ("perceived stigma") using parallel 15-item scales. We estimated mean stigma scores, computed inequality measures at each wave, and decomposed inequality by sociodemographic characteristics. Leveraging the cohort design, we estimated intraclass correlation coefficients and rank-order stability over time. ResultsBoth public and perceived stigma declined substantially from baseline to endline and became concentrated in an increasingly smaller subgroup of the population. Theil decomposition failed to identify any stratifying variables that explained more than 3% of this variation: nearly all the inequality in HIV stigma occurred within population subgroups rather than between them. In longitudinal analyses, public stigma showed trait-like properties (intraclass correlation coefficient=0.35; 95% CI, 0.31-0.38) and meaningful rank-order stability (baseline-to-endline r=0.41). Perceived stigma showed no rank-order stability, no appreciable between-person variance, and universal convergence to low levels regardless of baseline. ConclusionsBoth public and perceived HIV stigma declined substantially in this rural Ugandan population, but remaining public stigma has become concentrated within a persistent minority. Sociodemographic profiling to target individuals who carry persistently negative attitudes toward people with HIV is unlikely to succeed.

BackgroundRoutine viral load monitoring is central to assessing treatment effectiveness in HIV care, and dolutegravir (DTG)-based regimens are now preferred in many treatment programmes. However, national routine data analyses comparing 48-week viral load suppression across antiretroviral therapy initiation regimens in Tanzania remain limited. MethodsWe conducted a retrospective cohort analysis using routinely collected HIV programme data from Tanzanias National AIDS, STIs and Hepatitis Control Programme database. After de-duplication and data processing, the working analysis warehouse contained 49,547 patients and 1,008,137 visits. The primary analysis included 6,991 patients with a valid viral load measured 48 weeks after initiation of antiretroviral therapy. Viral suppression was defined as a viral load <1,000 copies/mL. We compared suppression between DTG-based and non-DTG-based initiation groups and across individual initiation regimens. Treatment change episodes and early DTG switching patterns were summarized as secondary analyses. ResultsOf the 6,991 included patients, 6,113 (87.4%) achieved viral load suppression at 48 weeks. Suppression was higher among DTG initiators than non-DTG initiators (917/1,000, 91.7% vs. 5,196/5,991, 86.7%). TDF+3TC+EFV was the most common non-DTG initiation regimen, whereas TDF+3TC+DTG was the most common regimen among DTG initiators. ConclusionsViral suppression at 48 weeks was high overall but was higher among patients initiated on DTG-based regimens than among those initiated on non-DTG regimens. By anchoring outcomes to a fixed post-initiation time point, this study complements existing Tanzanian evidence on viral load testing uptake and geographic variation. It provides regimen-specific insights into the effectiveness of early treatment under routine programme conditions.

IntroductionHIV testing for children of women living with HIV (WLHIV) is an efficient method of diagnosing HIV in children. We analyzed pooled data from 13 Population-based HIV Impact Assessments (PHIA) conducted from 2015 through 2019 to determine the gap in diagnosing HIV in children of WLHIV. MethodsIn each PHIA, children younger than 15 years in a subset of households were sampled for HIV testing. Mother-reported responses on childs status were linked to maternal interviews and biomarker data. Analysis was restricted to children whose mothers were alive, older than 15 years and aware of their HIV-positive status prior to the survey. We calculated weighted proportions of children who were never previously tested and proportion of children living with HIV (CLHIV) with no evidence of antiretroviral treatment (ART) use (categorized as newly diagnosed). Survey weights were pooled across all PHIAs to account for survey design and nonresponse. ResultsOf 4,234 WLHIV, 3,436 were aware of their HIV status and had at least one child (n=6,173) for whom responses were obtained. Of the 6,173 children, 43.5% (n=2,371) were reported as never been tested. Overall, 5,500 children provided blood for HIV testing during the survey. Newly diagnosed test positivity was 1.7% (90/5,191); 2.9% (61/2,120) among those with reported unknown HIV status and 0.9% (29/3,071) among those with reported HIV negative status. Among children with reported HIV positive status, 94.5% were confirmed by survey testing and of these, 91% had antiretrovirals (ARVs) detected. ConclusionsOver 40% of children of WLHIV who were aware of their HIV positive status had never been tested for HIV. HIV positivity ranged between 0.9% to 2.9% while 9.0% of children known to be HIV positive were not on ART. The study calls for renewed efforts to enhance testing of children and treatment linkage for those diagnosed with HIV.

Understanding the dynamics of HIV epidemics is important to control them effectively. Classical methods that mainly rely on occurrence data are limited by the fact that an unknown part of the epidemic eludes sampling. Since the early 2000s, phylodynamic methods have enabled the estimation of key epidemiological parameters from virus genetic sequence data. These methods have the advantage of being less sensitive to partial sampling and to provide insights about epidemic history that even predates the first samples. In this study, we analysed 2,205 HIV sequences from the French ANRS PRIMO C06 cohort. We identified and were able to reconstruct the temporal dynamics of two large clades that represent the HIV-1 epidemics in the country. Using Bayesian phylodynamic inference models, we found that the first clade, from subtype B, originated in the end of 1970s, grew rapidly during the 80s before decreasing from 2000 to 2015 and stagnating since then. The second clade, from circulating recombinant form CRF02 AG, emerged and spread in the 80s, grew again in the early 2000s, before declining slightly. We also estimated key epidemiological parameters associated with each clade. Finally, using numerical simulations, we investigated prospective scenarios and assessed the possibility to meet the 2030 UNAIDS targets. This is one of the rare studies to analyse the HIV epidemic in France using molecular epidemiology methods. It highlights the value of routine HIV sequence data for studying past epidemic trends or designing public health policies. Author summaryDespite huge progress in prophylaxis and treatment, HIV epidemics remain a major public health issue in most countries. Therefore, understanding, tracking, and predicting epidemic dynamics is essential to design optimal prevention and screening strategies. A strong limitation is that most methods rely on occurrence data and are very sensitive to the unsampled portion of the epidemic (also known as the HIV hidden epidemic). To address this issue, we take advantage of phylodynamics methods that rely on viral sequence data. Thanks to data from the ANRS Primo cohort, we identify two epidemics present in France since the early 1980s that exhibit consistent, but some times different, dynamics. By simulating future scenarios, we demonstrate that the UNAIDS goal to reduce new HIV infections by 90 % from 2010 by 2030 is uncertain, at least for one of the two epidemics we consider. This is one of the first studies to leverage phylodynamic methods to analyse the French HIV epidemic. It also highlights how routinely-generated genomics data can enable detailed analyses that facilitate the design of efficient public health policies.

Background: Pre-exposure prophylaxis (PrEP) is an effective HIV prevention tool, yet uptake and adherence remain low in Kenya despite integration into national HIV prevention plans since 2017. Intimate partner violence (IPV) is a prevalent HIV-related syndemic that presents barriers to PrEP engagement. While IPV's impact on women's PrEP use has been documented, less is known about IPV prevalence among men and its association with PrEP eligibility. This study aimed to determine IPV prevalence and explore correlates among PrEP-eligible men and women in coastal Kenya. Methods: This secondary analysis used data from the "Tambua Mapema Plus" trial conducted at six healthcare facilities in coastal Kenya among HIV-negative participants who were sexually active in the last 6 weeks and PrEP-eligible based on Kenya's Rapid Assessment Screening Tool. IPV was assessed through screening questions covering physical, verbal, and sexual violence experiences. Participants with ongoing IPV were excluded for safety. Among 1,500 intervention participants, 638 (402 women, 236 men) met PrEP eligibility criteria. Modified Poisson regression with robust standard errors was used to identify factors associated with IPV. Results: Overall, 24.1% reported lifetime IPV exposure, with 5.6% reporting past-month IPV. Women experienced higher rates of verbal (14.9% vs 11.0%), physical (15.2% vs 9.7%), and sexual IPV (11.2% vs 6.4%). Participants who had children (adjusted risk ratio [ARR]=2.09, 95%CI 1.32?3.32) or engaged in sex work (ARR=1.81, 95%CI 1.13?2.80) had increased IPV risk. In multivariable analysis, women with children had higher IPV risk (ARR=2.30, 95%CI 1.29?4.24), while men engaging in sex work had elevated risk (ARR=2.37, 95%CI 1.15?4.68). Discussion: IPV prevalence was substantial. Sex work emerged as a risk factor for both sexes, while having children increased risk among women. High IPV prevalence among PrEP-eligible individuals underscores the need for integrated IPV risk assessment in PrEP programs to improve HIV prevention effectiveness in Kenya.

Introduction Viral load monitoring is central to assessing antiretroviral therapy (ART) effectiveness, yet timely access remains challenging in resource-constrained settings. Point-of-care (POC) triage tests may improve ART monitoring efficiency by identifying clients requiring confirmatory viral load testing while reducing unnecessary testing among those likely to be virally suppressed. We explored perceptions of integrating a POC triage test that measures interferon-gamma-induced protein 10 (IP-10) - a chemokine strongly correlated with HIV viral load - into routine ART monitoring among people living with HIV (PLHIV) on ART, healthcare providers, and HIV programme stakeholders. Methods This qualitative study was nested within a clinical evaluation of the IP-10 POC triage test in two primary healthcare facilities in Maputo Province, Mozambique (2023-2024). We conducted three rounds of interviews with PLHIV on ART who underwent IP-10 testing, and one-off interviews with healthcare providers and HIV programme stakeholders across different health system levels. PLHIV were purposively sampled to capture diverse IP-10 and viral load outcomes. Interviews explored experiences of ART monitoring, perceptions of the IP-10 POC test, and implementation considerations. Data were analysed thematically using an inductive-deductive approach. Results Routine viral load monitoring was widely valued and understood as essential for treatment adherence and effectiveness, but participants described barriers including laboratory delays, access challenges, and health system constraints. The IP-10 POC triage test was broadly acceptable; same-day results were perceived to reduce anxiety, support adherence, and enable timely clinical decision-making. Providers and stakeholders emphasised its potential to improve monitoring efficiency by prioritising clients who require confirmatory viral load testing and adherence support. Concerns were raised regarding test accuracy and the need to maintain confirmatory viral load testing, underscoring the importance of clear communication and client education. Successful implementation would require training, workflow integration, and quality assurance. Conclusions An IP-10 POC triage test could strengthen ART monitoring by enabling same-day identification of clients requiring confirmatory viral load testing and targeted adherence support. By reducing unnecessary viral load testing for virally suppressed clients, it may contribute to more efficient monitoring and support differentiated care approaches. Careful integration into existing ART monitoring algorithms will be critical to maximise impact.

BackgroundRecent multiomic analyses identify metformin-inducible genes, such as DDIT4, as predictors of delayed HIV rebound, suggesting a "cell-extrinsic" role for low systemic inflammation in viral control. We sought to validate this inflammatory "cooling" in a large-scale human population. MethodsUsing Olink proteomics from the UK Biobank (N = 502,493), we evaluated associations between metformin use and inflammatory markers (IL-6, CXCL10, GZMB) in a diabetic cohort (N = 18,548). Stepwise regression was used to adjust for co-medications (statins) and glycemic control (HbA1c). ResultsMetformin use was associated with significantly lower levels of IL-6 (p = 0.0049) and CXCL10 (p < 0.001) after adjusting for age, BMI, and statin use. In exploratory analyses of participants with HIV (N = 61), metformin users showed directionally lower mean IL-6 and CXCL10. However, associations in the primary cohort were attenuated upon adjustment for HbA1c, indicating that metformins systemic anti-inflammatory effect is largely mediated by its metabolic efficacy. ConclusionsMetformin use is associated with a reduction in master regulators of inflammation, independent of common co-medications. These findings suggest that metformin promotes the systemic "cell-extrinsic" environment required for HIV control via its metabolic effects, providing a population-level substrate for the "block-and-lock" mechanisms observed in clinical cohorts.

BackgroundStigma remains a pervasive barrier to curbing the spread of human immunodeficiency virus (HIV) among adolescents and young adults in Lima, Peru. Social media offers a promising avenue for scalable, youth-centered stigma reduction, but few interventions have been rigorously evaluated in this context. ObjectiveWe evaluated the potential of a social media campaign to reduce perceived HIV-related stigma among young adults living with HIV. This involved a sequential explanatory mixed-methods study, including a randomized evaluation, followed by focus groups to understand the findings. Methods150 young adults (aged 18-29 years) living with HIV (YLWH) were randomized to receive information on social media from one of the following: (1) the control account; (2) the control account and the social media campaign accounts (Instagram and TikTok); or (3) the control account, the campaign accounts, and the accounts of participating influencers. Perceived stigma was measured via pre- and post-campaign surveys using Spanish versions of the abridged Berger HIV Stigma Scale and the Stigma Stress Scale. Focus groups and interviews were conducted with a purposive sample of participants to contextualize quantitative results. Qualitative data were analyzed using Framework Analysis. ResultsMean changes in HIV Stigma and Stigma Stress scores were small and not statistically significant. Post-hoc as-treated analyses supported these findings. Fidelity to intervention allocation was low to moderate, depending on the metric considered. Qualitative data suggested that the campaign positively impacted participants perceived stigma and that personal circumstances, crossover, frequency of exposure to content, and issues related to completing study questionnaires contributed to the lack of meaningful change in stigma scores. ConclusionsWhile quantitative data did not support that exposure to a social media campaign led to meaningful reductions in HIV-related stigma, qualitative data suggested that the campaign had a positive impact and that limitations in the study design, together with external factors, may have obscured benefits in quantitative analyses.

BackgroundHIV transmission is characterised by a low per-act probability, a relatively high proportion of multiple variant transmission events, and a plateauing of transmission risk at high viral loads. No existing mechanistic model can simultaneously recapitulate all of these observations, thereby limiting our ability to predict unobserved transmission phenomena and evaluate prevention strategies. MethodsWe developed a suite of mathematical models that encode an empirically plausible set of transmission mechanisms and then fit these models within a Bayesian framework to available epidemiological data to identify which set of mechanisms are sufficient to recapitulate the data. Following formal model comparison, we embedded the best-fit model into a phylodynamic framework and calibrated it using Approximate Bayesian Computation, to assess whether phylogenetic trees from individual transmission pairs were both consistent with the model and informative. Finally, we further validated our most likely model against two large prospective studies (PARTNER1 and STEP). ResultsOur calibrated model predicts that for each systemic infection, approximately four to five transient infections occur--exposure events in which viral replication occurs but is stochastically extinguished--consistent with indirect empirical evidence from the STEP vaccine trial. The model predicts a transmission rate of fewer than 0.05 systemic infections per 100 couple-years follow up from individuals with undetectable viral load, providing a mechanistic basis for the negligible risk observed in the PART-NER1 study. The model also predicts a strong link between the number of viral particles transmitted and the number of variants establishing infection, modulated by the transmitters infection stage. Recalibrating for men who have sex with men indicated that higher transmission rates in this population are explained by a single parameter: a greater probability of permissive conditions for infection. These predictions emerge from a model in which three mechanisms were needed to explain the epidemiological data: highly infrequent permissive conditions within the exposed partner, stage-dependent differences in the probability that infected cells establish systemic infection, and target cell limitation at the site of infection. The model was further validated against phylogenetic data from 48 transmission pairs, where combining mechanistic and phylogenetic information sharpened posterior estimates of time since infection in the majority of cases. ConclusionThree biologically grounded mechanisms are sufficient to explain the key features of HIV transmission. The resulting model provides a principled and mechanistic basis for estimating transmission risk and for designing interventions to reduce it.

Delayed diagnosis and poor antiretroviral therapy (ART) adherence remain primary drivers of HIV-related morbidity in low-resource settings, yet real-world AI validation at scale is lacking. We conducted a retrospective validation study using two publicly available, de-identified datasets: a Quality of Care cohort of 27,288 HIV-positive patients on ART across multiple healthcare facilities, and the CEPHIA multi-country assay database comprising 165,444 specimen records from six countries. Four machine learning classifiers were evaluated using 10-fold stratified cross-validation with SMOTE applied strictly to training folds. Explicit data leakage prevention, ablation analysis, calibration assessment, and bootstrap confidence intervals were applied. Economic projections used one-way sensitivity analysis. This study adheres to TRIPOD reporting guidelines. Random Forest achieved AUC-ROC of 0.9753 (95% CI: 0.970-0.975), sensitivity 87.3% (95% CI: 86.4-88.2%), specificity 95.7% (95% CI: 95.2-96.2%), and Brier score 0.079. Ablation testing confirmed robustness (AUC 0.963 without the primary predictor). Temporal validation on held-out future patients yielded AUC 0.772 (95% CI: 0.744-0.802), confirming generalisation across time. Real-world analysis revealed median diagnosis-to-ART delay of 74 days, with 47.3% of patients exceeding 90 days and 36.7% presenting with CD4 below 200 cells per microlitre. Multi-country CEPHIA analysis identified 18.6% HIV recency within the 130-day early-intervention window. Decision curve analysis confirmed net clinical benefit across threshold probabilities 0.03-0.45. Subgroup analysis demonstrated consistent AUC across sex, age, CD4 strata, and WHO staging (max difference 0.051). Economic modelling projected base-case savings of USD 415 per patient (USD 2.07 million per 5,000-patient cohort). These findings provide large-scale empirical evidence that AI-driven informatics can predict ART adherence failure and quantify systemic care gaps, offering a scalable framework for equitable HIV care delivery in resource-limited settings. Prospective external validation is required before clinical deployment.

Objectives: Quantify hazardous alcohol consumption prevalence among individuals at risk of acquiring HIV infection and its association with high-risk sexual behaviors and incident HIV in 11 Eastern and Southern African countries. Design: Secondary analysis of 16 nationally-representative household surveys (2015-2023). Methods: The study included sexually active individuals aged [&ge;]15 years. Alcohol use patterns were classified using the AUDIT-C (non-drinkers/low-risk drinkers/hazardous non-binge drinkers/hazardous binge drinkers). Outcomes included high-risk sexual behaviors, recent HIV infection, and undiagnosed HIV infection. Survey-weighted alcohol use prevalence and logistic regression were estimated by gender, adjusting for sociodemographic covariates. Model outputs were used to estimate change in incident infections when removing excess risks associated with alcohol use patterns. Results: Analyses included 251,931 participants. Across countries, 5.8%-21.1% reported hazardous binge drinking, and 3.7%-15.7% reported hazardous non-binge drinking, with large gender differences. Sexual risk behaviors increased with drinking severity among men and women. Compared with non-drinkers, alcohol use was associated with higher odds of undiagnosed HIV infection; adjusted odds ratios ranged from 1.32 (1.16-1.50) for low-risk drinkers to 1.52 (1.34-1.72) for hazardous binge drinkers among men, and 1.28 (1.13-1.46) to 1.55 (1.31-1.82) among women. Simulated removal of alcohol-associated excess risk reduced undiagnosed HIV by 15.1% (10.9%-19.4%) among men and 5.8% (4.0%-7.9%) among women. Estimates for recent HIV infection followed a similar pattern but with larger uncertainty. Conclusions: Hazardous alcohol use was associated with sexual risk and HIV infection in Eastern and Southern Africa. Reaching individuals who use alcohol with effective HIV prevention may reduce HIV acquisition risk across the region.